TEMPEST THERAPEUTICS, INC.

Consensus Tempest Therapeutics, Inc.

Stocks

TPST

US87978U2078

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-10-19 EDT			5-day change	1st Jan Change
0.6001 ^USD	-3.86%		-19.20%	-79.09%

10-14	Tempest Therapeutics, Inc. Announces Appointment of John W. Frederick as Director	CI
10-07	Sensorion: Louis J. Arcudi III appointed chief financial officer

Evolution of the Average Target: Tempest Therapeutics, Inc.

Evolution of the Average Target - Tempest Therapeutics, Inc.

Evolution of the Target Price: Tempest Therapeutics, Inc.

Evolution of the Target Price - Tempest Therapeutics, Inc.

Changes in Analyst Recommendations: Tempest Therapeutics, Inc.

65bff8cb54d4b63102b283f7ff3df24.3hnH0kxqybHX9HjQORrJ_MkkS3mdjYSzMtbfYlR1ICI.k1eLgWEOi9CYpj-jY3KEyaxXOBX3xvOEH5KoLz4cY1HvT6uDOj2a5OGDMQ~185e75528e82b4ec1b152d94fc40140e

Analysts' recommendations: Tempest Therapeutics, Inc.

01-22	HC Wainwright Upgrades Tempest Therapeutics to Buy From Neutral, Price Target is $11	MT
25-04-10	HC Wainwright Downgrades Tempest Therapeutics to Neutral From Buy	MT
24-03-14	Scotiabank Initiates Tempest Therapeutics With Sector Outperform Rating, Price Target is $13	MT
23-10-11	HC Wainwright Raises Price Target on Tempest Therapeutics to $47 From $35, Maintains Buy Rating	MT
23-03-23	Piper Sandler Adjusts Tempest Therapeutics' Price Target to $6 From $10, Keeps Overweight Rating	MT
22-09-15	Ladenburg Thalmann Starts Tempest Therapeutics at Buy With $8 Price Target	MT
22-05-13	HC Wainwright Adjusts Tempest Therapeutics Price Target to $35 From $51, Maintains Buy Rating	MT
22-04-28	Piper Sandler Adjusts Price Target on Tempest Therapeutics to $20 From $23, Reiterates Overweight Rating	MT
21-10-21	Tempest Therapeutics : William Blair Initiates Tempest Therapeutics at Outperform Rating	MT
21-07-13	Tempest Therapeutics : HC Wainwright Starts Tempest Therapeutics at Buy With $51 Price Target	MT
21-07-06	Tempest Therapeutics : Piper Sandler Starts Tempest Therapeutics at Overweight With $23 Price Target	MT

More recommendations

Other Biotechnology & Medical Research

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	TEMPEST THERAPEUTICS, INC.			-	-	+1,021.44%
	WUXI APPTEC CO., LTD.					+32.97%
	LONZA GROUP AG					+14.74%
	ARGENX SE					+38.45%
	IQVIA HOLDINGS INC.					+12.07%
	BEONE MEDICINES AG					+18.26%
	REVOLUTION MEDICINES, INC.					+44.87%
	CELLTRION, INC.					+38.06%
	WUXI BIOLOGICS (CAYMAN) INC.					+24.78%
	GENMAB A/S					+8.87%
	Average					+125.45%
	Weighted average by Cap.					+26.78%

See all sector performances

Analysts' Consensus

Sell

Consensus

Buy

Mean consensus

BUY

Number of Analysts

1

Last Close Price

0.6001USD

Average target price

7.000USD

Spread / Average Target

+1,066.47%

High Price Target

7.000USD

Spread / Highest target

+1,066.47%

Low Price Target

7.000USD

Spread / Lowest Target

+1,066.47%

Analyst Consensus Detail

Analyst consensus - Tempest Therapeutics, Inc.

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Tempest Therapeutics, Inc.

Stock Market
Stocks
TPST Stock
Consensus Tempest Therapeutics, Inc.

The best tools reserved for subscribers to boost the performance of your investments!